Investor Home

Investor Home

Corporate Profile

Nabriva is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. We are developing both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP) and intend to develop lefamulin for additional indications other than pneumonia.

Lefamulin

Nabriva’s lead pleuromutilin product candidate, lefamulin, is being studied for the treatment of moderate to severe CABP. We have completed the LEAP 1 Phase 3 trial ... More >>

Recent Newsmore >
12/13/17
Nabriva Therapeutics Added to NASDAQ Biotechnology Index
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that it has been selected for addition to the NASDAQ Biotechnology Index®, which will become effective prior to the open of U.S. markets on Monday, December 18, 2017. ... 
12/04/17
Nabriva Therapeutics Announces Completion of Enrollment in LEAP 2, a Phase 3 Clinical Trial Evaluating Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia in Adults
Company remains on track to report topline results in Spring 2018 DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that it has completed enrollment in its second lefamulin evaluation against pneumonia (LEAP 2) Phase... 
11/30/17
Nabriva Therapeutics to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that members of the company’s management team will participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference on Wednesday, December 13, 2017. Th... 
Upcoming Eventsmore >
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.